Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00777127
Other study ID # X-03016-3271
Secondary ID 2007-004884-24
Status Completed
Phase Phase 4
First received
Last updated
Start date December 2008
Est. completion date November 2012

Study information

Verified date January 2013
Source Viatris Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream or Solaraze® 3% gel on the face or the scalp. In particular, it should be found out whether the healing effect of these two medications on the skin lesions (i.e. the damaged skin parts) can be maintained for a prolonged period.


Recruitment information / eligibility

Status Completed
Enrollment 258
Est. completion date November 2012
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Immunocompetent patient. - A study treatment area must be identifiable: Minimum of 5 and maximum of 10 typical visible AKs in one contiguous area of up to 50 cm2 on the face or scalp. The eyelids, the inside of the nostrils or ears, or the lip area inside the vermilion border must not be part of this area. - A positive histological finding for AK grade I or II (see Section 7.1.1.2). This will be determined from the most suspicious lesion in the STA and there from the most pathological area biopsied during screening visit. This analysis will be done by the central histopathological laboratory. - Willingness to comply with the obligations of the study. Exclusion Criteria: Safety concerns: - History of allergic reaction to imiquimod, diclofenac, acetyl salicylic acid, other non steroidal anti-inflammatory drugs (NSAID), hyaluronic acid, or relevant excipients. - Pregnancy, breast-feeding or planned pregnancy during the study. Women of child bearing potential not using a highly effective method of birth control defined as those which result in a low failure rate (i.e. <1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal ligation or vasectomised partner. Lack of suitability for the study: - Presence of AK lesions in the STA with clinically marked hyperkeratosis or hypertrophy as seen in cutaneous horns. - Any topical AK treatment including imiquimod or diclofenac, or any systemic AK treatment such as systemic retinoids, or any surgical AK treatment at the STA within the last 2 months prior to randomisation. - Persisting AK lesion at screening visit following topical treatment with imiquimod or diclofenac in the STA. - Topical treatment with imiquimod or diclofenac anywhere else on the body within the last 2 months prior to randomisation. - Presence of any histologically confirmed skin tumour in the STA: in situ SCC including Bowen's disease, invasive SCC, basal cell carcinoma, or other malignant tumours. - Any dermatological disease or condition that may exacerbate by treatment with imiquimod or diclofenac (e.g. rosacea, psoriasis, atopic dermatitis). - Any dermatological disease or condition in the STA that causes difficulty with examination (e.g. eczema). - Systemic immunomodulatory treatment such as interferon, azathioprine, cyclosporine, retinoids, any oral or injectable corticosteroids, or inhaled or nasal corticosteroids with dosages of >1200 µg/day beclomethasone or equivalent within 4 weeks before start of study treatment. - History of any malignant tumour with high tumour burden or any systemic antitumour treatment (incl. radiotherapy). - History of any malignant skin tumour having metastasised or where metastasis could be expected. - History of severe cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrine, metabolic, mental, neurological, or other disease within the last two years. - Mentally incapacitated patient. - Present or history of drug or alcohol abuse within the last 3 years. Administrative reasons: - Exposure to an investigational product within the last 3 months. - Lack of ability or willingness to give informed consent. - Age below 18 years. - Lack of willingness to have personal study related data collected, archived or transmitted according to protocol. - Anticipated non-availability for study visits/procedures. - Vulnerable subjects (such as persons kept in detention).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Imiquimod
One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
Diclofenac
Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.

Locations

Country Name City State
Austria Hospital Feldkirch, Department for Dermatology and Venereology Feldkirch
Austria Medical University Graz, University Clinic for Dermatology and Venereology Graz
Austria Medical University Innsbruck, University Clinic for Dermatology and Venereology Innsbruck
Austria Medical University Vienna, Department for General Dermatology Vienna
France CHU St Jacques, Department for Dermatology Besancon Cedex
France Hospital Sainte Marguerite, Department for Dermatology and Venereology, Pavilion 3, First Floor Marseille
France CHU Nice - Hospital Archet 2, Department for Dermatology Nice
France Hospital Saint-Louis, Derpartment for Dermatology Paris
France Hospital Center Lyon South, Department for Dermatology and Immuno-Allergology Pierre Benite
Germany Licca Clinical Research Institute Augsburg
Germany Charite - Medicine University Berlin, Dermatoma Center, Clinic for Dermatology, Allergology and Venereology Berlin
Germany Medical Practice Dominicus / Bockhorst Duelmen
Germany Medical practice Düsseldorf
Germany University Clinic Düsseldorf, Clinic for Dermatology Düsseldorf
Germany Clinic and Medical Faculty of Johann Wolfgang Goethe-University, Center for Dermatology and Venereology Frankfurt am Main
Germany SCiderm GmbH Hamburg
Germany Medical Practice Hannover
Germany University Clinic Schleswig-Holstein, Campus Kiel, Clinic for Dermatology, Venereology and Allergology Kiel
Germany Medical Department of Otto-von-Guericke-University Magdeburg, University Clinic for Dermatology and Venereology Magdeburg
Germany Department of Dermatology J. Gutenberg-University Mainz, Clinical Research Center Mainz
Germany Science, Onco & Beauty GbR, Practice for Dermatology and Medical Cosmetics Mönchengladbach
Germany University Clinic Münster, Clinic and Polyclinic for Skin Diseases Münster
Germany Clinic University Regensburg, Clinic and Polyclinic for Dermatology Regensburg
Germany Derma Center Vechta Vechta
Germany Centrovital Witten
Germany Medical practice for Dermatology and Venerology Wuppertal

Sponsors (1)

Lead Sponsor Collaborator
MEDA Pharma GmbH & Co. KG

Countries where clinical trial is conducted

Austria,  France,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence with respect to the study treatment area until month 12 A patient is classified as recurrent when cleared at Visit Week 20 and having later on at least one clinically diagnosed AK lesion in the study treatment area week 20 until month 12
Secondary Time to recurrence 3 years
Secondary Long-term outcome with respect to development of SCC (in situ and/or invasive) 3 years
Secondary Need of rescue treatment 3 years
Secondary Haematological changes 20 weeks
Secondary Cosmetic outcome. 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT03013647 - Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization N/A
Completed NCT02674048 - Metvix Daylight PDT in Actinic Keratosis
Completed NCT02239679 - Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy Phase 2
Completed NCT02421471 - PMS to Evaluate the Safety and Efficacy of Picato® Gel
Completed NCT01686152 - Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis Phase 3
Completed NCT01449513 - PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy Phase 1
Completed NCT01444989 - Development and Validation of a Quality of Life Instrument for Actinic Keratosis N/A
Terminated NCT01525329 - Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease Phase 3
Terminated NCT01203878 - Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Phase 4
Completed NCT00989313 - A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study Phase 3
Completed NCT00306800 - Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp Phase 3
Completed NCT00375739 - Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses Phase 2
Completed NCT03285490 - A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004) Phase 3
Completed NCT03319251 - Biomarker Database Registry for Photodynamic Therapy
Completed NCT02866695 - Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Phase 4
Completed NCT02952898 - Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses Phase 3
Completed NCT02984072 - Menthol for PDT Pain Relief Phase 4
Recruiting NCT03684772 - Topical Ionic Contra-Viral Therapy in Actinic Keratosis Phase 2
Completed NCT02938715 - Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil N/A
Completed NCT02878382 - Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT N/A